검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | APRIL CAR-T cells |
Overview Company | Yake Biotechnology Ltd. |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Multiple Myeloma in Relapse; Multiple Myeloma, Refractory |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | CAR T-cell-mediated binding and killing of myeloma cells which might contribute to the efficacy of |
MoA Biomarker | BCMA but with a much low |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial.. Systemic lupus erythematosus (SLE) is a classic systemic autoimmune disease mediated by autoantibodies. Chimeric antigen receptor T (CAR-T) cell therapy, known for its success in cancer, has shown promise in achieving durable B cell depletion and long-term r… |
Toxicology CRS | 88% |
Clinical OS | 3 |
Clinical Result source | ClinicalTrials.gov NCT03287804 |
Clinical Data Tier / Score | A · 16 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | APRIL CAR-T cells |
Overview Company | Yake Biotechnology Ltd. |
Overview Modality | CGT |
Overview Target | FRα |
Overview Indication | Multiple Myeloma in Relapse; Multiple Myeloma, Refractory |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | CAR T-cell-mediated binding and killing of myeloma cells which might contribute to the efficacy of |
MoA Biomarker | BCMA but with a much low |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial.. Systemic lupus erythematosus (SLE) is a classic systemic autoimmune disease mediated by autoantibodies. Chimeric antigen receptor T (CAR-T) cell therapy, known for its success in cancer, has shown promise in achieving durable B cell depletion and long-term r… |
Toxicology CRS | 88% |
Clinical OS | 3 |
Clinical Result source | ClinicalTrials.gov NCT03287804 |
Clinical Data Tier / Score | A · 16 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교